menu
    • menu
    [{"orgOrder":0,"company":"AUM Biosciences","sponsor":"HANDOK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Small molecule","year":"2021","type":"Collaboration","leadProduct":"CHC2014","moa":"Pan-TRK","graph1":"Oncology","graph2":"Phase I","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ AUM Biosciences","highestDevelopmentStatusID":"6","companyTruncated":"AUM Biosciences \/ AUM Biosciences"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"SPRIM Global investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Small molecule","year":"2021","type":"Series A Financing","leadProduct":"AUM001","moa":"MNK","graph1":"Oncology","graph2":"Undisclosed","graph3":"AUM Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"AUM Biosciences \/ SPRIM Global investments","highestDevelopmentStatusID":"1","companyTruncated":"AUM Biosciences \/ SPRIM Global investments"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Asymchem Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"AUM601","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"AUM Biosciences \/ Asymchem","highestDevelopmentStatusID":"6","companyTruncated":"AUM Biosciences \/ Asymchem"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"HANDOK","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"CHC2014","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AUM Biosciences \/ Handok","highestDevelopmentStatusID":"6","companyTruncated":"AUM Biosciences \/ Handok"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"AUM001","moa":"MNK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AUM Biosciences \/ MSD","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosciences \/ MSD"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"AUM001","moa":"MNK","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AUM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"AUM601","moa":"TRKA","graph1":"Oncology","graph2":"Phase I","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AUM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"AUM Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Mountain Crest Acquisition Corp. V","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Merger","leadProduct":"AUM001","moa":"MNK","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AUM Biosciences \/ Mountain Crest Acquisition Corp. V","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosciences \/ Mountain Crest Acquisition Corp. V"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"AUM001","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AUM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"AUM302","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AUM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AUM Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"AUM302","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AUM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"AUM Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"AUM Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"AUM001","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"AUM Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"AUM Biosciences \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"AUM Biosciences \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by AUM Biosciences

    Menu

    AUM Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUM001,Pembrolizumab,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AUM Biosciences Doses First Patient in Phase 2 Clinical Trial of AUM001 in Metastatic Colorectal Cancer

                            Details : AUM001 is a mRNA translation inhibitor that targets MNK 1/2 and the chokepoint of multiple pro-oncogenic signalling pathways, being investigated for the treatment of metastatic colorectal cancer.

                            Brand Name : AUM001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 30, 2023

                            Lead Product(s) : AUM001,Pembrolizumab,Irinotecan Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUM302

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AUM Biosciences Receives U.S. FDA Rare Pediatric Disease Designation for AUM302 for Treatment of Neuroblastoma

                            Details : AUM302 is a potential oral kinase inhibitor, combines with pan-PIM kinase, pan-PI3K and mTOR inhibition in single agent. It has the potential to inhibit multiple key intracellular pathways, increasing its ability to inhibit cancer cell growth and prevent...

                            Brand Name : AUM302

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 05, 2023

                            Lead Product(s) : AUM302

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUM302

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AUM Biosciences Receives FDA Orphan Drug Designation for AUM302 for the Treatment of Neuroblastoma

                            Details : AUM302 is a potential first-in-class oral kinase inhibitor rationally designed to uniquely combine pan-PIM kinase, pan-PI3K and mTOR inhibition in a single agent. AUM302 has shown promise with good tolerability and favourable drug properties.

                            Brand Name : AUM302

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 30, 2022

                            Lead Product(s) : AUM302

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUM001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AUM Biosciences Receives Human Research Ethics Committee Approval to Commence Phase II Clinical Trial of AUM00...

                            Details : AUM001 is highly selective translation inhibitor. In vitro, it was observed to selectively inhibit MAPK – interacting protein kinase (MNK) types 1/2 and is expected to thereby block phosphorylation of eIF4E, and in turn, interfere with CAP mediated RNA...

                            Brand Name : AUM001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 15, 2022

                            Lead Product(s) : AUM001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUM001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Mountain Crest Acquisition Corp. V

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to...

                            Details : AUM001 is a selective and synergistic MNK inhibitor as shown in current studies and expected to begin Phase 2 enrollment in the fourth quarter 2022. AUM601 is a promising therapy for TRK fusions and mutations within the kinase domain and is on track to e...

                            Brand Name : AUM001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 20, 2022

                            Lead Product(s) : AUM001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Mountain Crest Acquisition Corp. V

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUM601

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AUM Biosciences Receives FDA Orphan Drug Designation for AUM601 for the Treatment of Solid Tumors with the NTR...

                            Details : AUM601 is a highly selective, oral small molecule that inhibits not only pan-TRK (TRKA, TRKB, and TRKC), but also resistance mutations of TRKs, by blocking the activity of tyrosine kinases.

                            Brand Name : AUM601

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 18, 2022

                            Lead Product(s) : AUM601

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUM001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AUM Biosciences Announces FDA IND Authorization for Global Phase 2 Trial of Selection Translation Inhibitor AU...

                            Details : As a result, AUM plans to evaluate AUM001, in combination with MSD’s anti-PD-1 therapy KEYTRUDA (pembrolizumab), in a global Phase 2 clinical trial in patients with microsatellite stable colorectal cancer (MSS CRC).

                            Brand Name : AUM001

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 07, 2022

                            Lead Product(s) : AUM001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUM001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : MSD Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AUM Biosciences Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate AUM001 in Com...

                            Details : This collaboration with MSD marks a major milestone and enables the joint clinical development of AUM001 in combination with KEYTRUDA. As a monotherapy, AUM001 demonstrated encouraging safety, tolerability and target engagement in two Phase 1 studies.

                            Brand Name : AUM001

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 05, 2022

                            Lead Product(s) : AUM001,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : MSD Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CHC2014

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : HANDOK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AUM Biosciences and HANDOK Presented Phase 1 Data for AUM-601 at ESMO Targeted Anticancer Therapies Congress 2...

                            Details : AUM-601 (CHC2014), a selective second-generation “Pan-TRK” Inhibitor was safe and well-tolerated at dose levels of 50 to 300 mg QD, as recommend Phase 2 dose (RP2D) based on PK profile and safety results.

                            Brand Name : AUM601

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 19, 2022

                            Lead Product(s) : CHC2014

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : HANDOK

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            AUM Biosciences

                            Singapore arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AUM601

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Asymchem Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AUM Biosciences Identifies Asymchem as the CDMO Partner of Choice for their Novel TRK inhibitor

                            Details : Under the terms of the agreement, AUM and Asymchem agree to collaborate on the process development, and the clinical and commercial production, of AUM 601, which is a highly selective oral small-molecule inhibitor of the tropomyosin receptor kinase for t...

                            Brand Name : AUM601

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 11, 2022

                            Lead Product(s) : AUM601

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Asymchem Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth